title: Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies.
abstract: With improvement in survival after cancer treatment, it is becoming increasingly important to examine treatment-related morbidity and mortality. Sarcomas can develop within the irradiated field after radiation therapy (RT) for gynecologic malignancies. We undertook a study to assess the outcome after treatment of postirradiation sarcoma (PIS) of the gynecologic tract. In reviewing our data and the literature, we compare the absolute risk of PIS and other radiation-associated second malignant neoplasms (SMNs) with the mortality risk of surgery and general anesthesia. Between 1955 and 1987, 114 patients with uterine sarcomas were seen at the University of California, Los Angeles (UCLA), Medical Center. Thirteen had a prior history of RT. Conditions for which these patients received RT included choriocarcinoma (one), menorraghia (four), cervical cancer (six), and ovarian cancer (two). RT doses were known in six cases and ranged from 4,000 to 8,000 cGy. Latency time from RT to the development of PIS ranged from 3 to 30 years, with a median of 17 years. Twelve patients were treated with surgery or additional RT. Two patients remain alive 5 months and 57 months, respectively, following salvage therapy. Five-year disease-specific survival for all patients is 17%. From our data and a review of the literature, we estimate that the absolute risk of PIS with long-term follow-up ranges from 0.03 to 0.8%. Postirradiation sarcoma of the gynecologic tract is a relatively rate event associated with a poor prognosis. Mortality risks of radiation-associated SMN are similar to mortality risks of surgery and general anesthesia. Given the large number of patients with gynecologic malignancies who can be cured or palliated with RT, concern regarding radiation sarcomagenesis should not be a major factor influencing treatment decisions.
authors.affiliation: Good Samaritan Hospital, Los Angeles, California, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Mark
authors.forename: J
authors.initials: J
authors.lastname: Poen
authors.forename: L M
authors.initials: LM
authors.lastname: Tran
authors.forename: Y S
authors.initials: YS
authors.lastname: Fu
authors.forename: J
authors.initials: J
authors.lastname: Heaps
authors.forename: R G
authors.initials: RG
authors.lastname: Parker
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D005833:Genital Neoplasms, Female / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016609:Neoplasms, Second Primary / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D012306:Risk; D016879:Salvage Therapy; D012509:Sarcoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D014594:Uterine Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*